Clinical trials: Plasmodium Falciparum and Plasmodium Vivax
Malaria
Malaria Active Epidemiology and Treatment Study
An observational cohort and malaria treatment study in Cambodia.
- Trial name
- NCT01280162
- Testing
- Dihydroartemisinin piperaquine
- Where
- Cambodia
- Volunteers
- 222 people, healthy volunteers welcome
- Sponsor
- Armed Forces Research Institute of Medical Sciences, Thailand
Malaria, Fever
Examination of ACT Implementation in a Vivax / Falciparum Co-endemic Area
In areas of which are co-endemic for vivax and falciparum malaria, treatments for the two diseases often differ and this may lead to mistreatment. This places an emphasis on diagnosis at the health service provision level.
- Trial name
- NCT00935688
- Testing
- Rapid diagnostic test
- Where
- 2 sites in Afghanistan
- Volunteers
- 4,200 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria Falciparum, Malaria Vivax
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects
OZ439 is a synthetic trioxolane that has potential value as a peroxide antimalarial agent. This was a Phase I, single-centre, multi-component, double-blind, randomised, placebo-controlled study in healthy male and female…
- Conditions
- Malaria Falciparum, Malaria Vivax, Healthy Volunteers
- Trial name
- NCT00928083
- Testing
- OZ439 50mg API capsules, OZ439 200mg API capsules, OZ439 400mg aqueous dispersion
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria
Malaria Studies in Cambodia
This study, conducted by the National Center for Parasitology, Entomology and Malaria Control of Cambodia s Ministry of Health and the National Institute of Allergy and Infectious Diseases, will explore whether the following…
- Trial name
- NCT00663546
- Where
- 3 sites in Cambodia
- Volunteers
- 1,978 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Falciparum Malaria
TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014
An antimalarial drug efficacy trial was conducted for artemether-lumefantrine (AL) and chloroquine (CQ) in the three (3) municipalities (Bataraza, Brookes and Rizal) of Palawan.
- Conditions
- Malaria, Falciparum Malaria, Vivax Malaria, Malaria Recrudescence
- Trial name
- TES (NCT04222088)
- Testing
- Arthemeter-lumefantrine, Chloroquine, Primaquine
- Volunteers
- 159 people
- Sponsor
- Research Institute for Tropical Medicine, Philippines
Malaria, Falciparum, Malaria, Vivax
A Randomised Trial of Artekin and Artesunate & Amodiaquine for Uncomplicated Malaria in Timika, Papua, Indonesia.
The primary aim of the comparative trial is to assess the relative safety and efficacy of two artemisinin containing regimens: amodiaquine plus artesunate (AAQ) and artekin both administered once daily for 3 days.
- Trial name
- NCT00157885
- Testing
- Amodiaquine plus artesunate; Artekin
- Where
- Indonesia
- Volunteers
- 400 people
- Sponsor
- Menzies School of Health Research
Drug Resistant Malaria, Asymptomatic Infections
Drug Resistance Among Asymptomatic Infection
A cross-sectional study will be conducted in selected 2 sentinel sites for assessment of drug resistance falciparum and vivax among asymptomatic infection in migrant workers in Myanmar.
- Conditions
- Drug Resistant Malaria, Asymptomatic Infections, Migrant Workers
- Trial name
- NCT03648411
- Testing
- Drug resistance molecular markers
- Where
- Burma
- Volunteers
- 765 people, healthy volunteers welcome
- Sponsor
- Department of Medical Research, Lower Myanmar
Malaria
Effectiveness of a Community-delivered Integrated Malaria Elimination (CIME) Model in Myanmar
In Myanmar, community health workers, known as malaria volunteers, have played a key role in reducing the malaria burden in the malaria control phase, providing essential malaria services in rural areas where the coverage of…
- Trial name
- NCT04695886
- Testing
- Community-delivered Integrated Malaria Elimination (CIME) intervention model
- Volunteers
- 6,440 people, healthy volunteers welcome
- Sponsor
- Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Malaria, Plasmodium Vivax Infection
Comparative Study of Thrombocytopenia in Plasmodium Vivax and Falciparum Malaria
This study aimed to compare platelet count patterns in patients infected with either Plasmodium vivax or Plasmodium falciparum, the two most common malaria species in Pakistan.
- Conditions
- Malaria, Plasmodium Vivax Infection, Plasmodium Falciparum Infection, Thrombocytopenia
- Trial name
- NCT07122232
- Where
- Pakistan
- Volunteers
- 177 people
- Sponsor
- Rafiullah Hotak
Malaria, Vivax, Malaria,Falciparum
Plasmodium Vivax Among Duffy Negative Population in Cameroon.
Although Plasmodium vivax (P. vivax), one of the five malaria species causing parasites, has the widest geographical distribution, it is rare in sub-Saharan Africa due to the absence of a red blood cell receptor (Duffy antigen)…
- Conditions
- Malaria, Vivax, Malaria,Falciparum, Malaria
- Trial name
- VIBRANT (NCT05058885)
- Where
- Cameroon
- Volunteers
- 900 people
- Sponsor
- University of Dschang
Plasmodium Falciparum Infection, Plasmodium Vivax Infection
Efficacy and Safety of Dihydroartemisinin-piperaquine (DHP) for the Treatment of Uncomplicated Malaria
This is an observational safety and efficacy study on dihydroartemisinin-piperaquine in Timika, Indonesia with a 42 day follow up period.
- Trial name
- NCT02353494
- Testing
- Dihydroartemisinin-Piperaquine
- Where
- Indonesia
- Volunteers
- 130 people
- Sponsor
- Menzies School of Health Research
Falciparum Malaria, Vivax Malaria
A Randomized Trial of Coartemether and Artekin for the Treatment of Uncomplicated Malaria in Papua, Indonesia.
This open randomized, parallel group, 6 week trial in two rural outpatient clinics will compare the safety and efficacy of a six dose coartemether regimen with 3 dose artekin regimen for the treatment of acute, uncomplicated…
- Trial name
- NCT00157833
- Testing
- Artekin / Coartemther
- Where
- Indonesia
- Volunteers
- 750 people
- Sponsor
- Menzies School of Health Research
Malaria
Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection
This study will assess efficacy, safety , tolerability and PK in uncomplicated adult malaria patients with P. vivax or P. falciparum infection after 3 day dosing with KAE609 at 30 mg/day
- Trial name
- NCT01524341
- Testing
- KAE609
- Where
- 3 sites in Thailand
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals
Uncomplicated Falciparum Malaria, Vivax Malaria
A Comparative Study of Artekin With Standard Malarial Treatment Regimes in Afghanistan
Malaria is a major public health problem in many provinces of Afghanistan the failure rate of chloroquine (CQ) and amodiaquine (AQ) treated Plasmodium falciparum(Pf) malaria has risen to more than 60% overall and as high as 90%…
- Trial name
- NCT00682578
- Testing
- Dihydroartemisinin + Piperaquine (Artekin), artesunate-sulphadoxin/pyrimethamine, chloroquine
- Where
- 4 sites in Afghanistan
- Volunteers
- 1,086 people
- Sponsor
- University of Oxford
Plasmodium Vivax Infection, Plasmodium Vivax Clinical Episode
Effect of Liver and Blood-stage Treatment on Subsequent Plasmodium Reinfection and Morbidity
This study specifically seeks to quantify the contribution of relapes to the burden of P. vivax infections and disease by determining on the effect of radical pre-erythrocytic and erythrocytic clearance on subsequent rates of…
- Conditions
- Plasmodium Vivax Infection, Plasmodium Vivax Clinical Episode, Plasmodium Falciparum Infection, Plasmodium Falciparum Clinical Episode
- Trial name
- NCT02143934
- Testing
- Primaquine, Chloroquine, Artemether Lumefantrine
- Where
- Papua New Guinea
- Volunteers
- 524 people, healthy volunteers welcome
- Sponsor
- Papua New Guinea Institute of Medical Research
Plasmodium Falciparum Malaria, Plasmodium Vivax Malaria
Targeting High Risk Populations With Enhanced Reactive Case Detection in Southern Lao Peoples Democratic Republic
This study assesses the effectiveness and feasibility of enhanced reactive case detection (RACD) targeting high-risk villages and forest workers for reducing Plasmodium falciparum and Plasmodium vivax transmission in southern Lao…
- Trial name
- COMBAT (NCT04416945)
- Testing
- Household Reactive Case Detection, RACD of cases' co-workers/co-travelers, Case Management and Follow-up
- Where
- Laos
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Plasmodium Falciparum Malaria, Plasmodium Vivax Malaria
DSM265 Phase IIa Investigation Treating Plasmodium Falciparum or Vivax
This will be a Proof-of-concept / Phase IIa, open label study to examine the efficacy of DSM265 in uncomplicated Plasmodium vivax and Plasmodium falciparum blood-stage malaria in adult patients.
- Trial name
- NCT02123290
- Testing
- DSM265 400mg, DSM265 xmg, DSM265 ymg
- Where
- Peru
- Volunteers
- 45 people
- Sponsor
- Medicines for Malaria Venture
Malaria
Performance Evaluation of Malaria Plus Rapid Diagnostic Tests (RDTs) for the Detection of Plasmodium Infections in Patients With Symptoms Suggestive of Malaria
This trial is part of a portfolio of studies designed to assess the clinical and operational performance of Abbott's NxTekTM Malaria Pf Plus and NxTekTM Malaria Pf/Pv Plus Rapid Test Devices.
- Trial name
- NCT05286359
- Testing
- NxTekTM Malaria Pf Plus Rapid Diagnostic Test Device
- Where
- Ethiopia
- Volunteers
- 1,023 people
- Sponsor
- Abbott Rapid Dx
Malaria
MMV390048 POC in Patients With P. Vivax and P. Falciparum Malaria
The present proof-of-concept Phase IIa study aims to confirm, in patients, the observed activity of MMV390048 against P. falciparum in pre-clinical models and the human Induced Blood-Stage Malaria (IBSM) challenge model, and to…
- Trial name
- NCT02880241
- Testing
- MMV390048
- Where
- 2 sites in Ethiopia
- Volunteers
- 8 people
- Sponsor
- Medicines for Malaria Venture
Malaria
A Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection
Part A -Cohort 1 DSM265 will be administered as a single dose (400 mg). For cohort 1 only, an additional single dose (400 mg) of DSM265 may be given if gametocytemia develops.
- Trial name
- DSMOZ-2 (NCT02573857)
- Testing
- DSM265, OZ439
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture